ACT 901Alternative Names: ACT-901; AFP-paclitaxel; Alpha-fetoprotein-paclitaxel conjugate; Third generation paclitaxel therapy
Latest Information Update: 20 Mar 2014
At a glance
- Originator Alpha Cancer Technologies
- Class Antineoplastics; Diterpenes; Drug conjugates; Paclitaxels; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 31 Dec 2013 Preclinical trials in Cancer in Canada (unspecified route) prior to December 2013